Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1. Schematic representation of the MANO method.

Published byAlessia Spinelli Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1. Schematic representation of the MANO method."— Presentation transcript:

1 Fig. 1. Schematic representation of the MANO method.
Schematic representation of the MANO method. Mouse 3T3 or Ba/F3 cells were infected with recombinant retrovirus expressing oncoproteins with corresponding 6-bp bar codes. Equal numbers of the stably transduced cells were mixed and cultured with different types of medium and/or treated with TKIs or vehicle. gDNA was harvested from the mixture of the remaining viable cells at the appropriate periods for each assay. The bar code sequences were PCR-amplified and subjected to deep sequencing on MiSeq sequencers to quantitate their relative abundance (a direct reflection of the cell number). To evaluate the transforming potential of each oncoprotein, the read number for each bar code was normalized to that of day 0. To evaluate the inhibition profile of test compounds across transduced clones in the mixture, the read number for each bar code was normalized to that of the vehicle-treated control. WT, wild-type. Shinji Kohsaka et al., Sci Transl Med 2017;9:eaan6566 Published by AAAS

Download ppt "Fig. 1. Schematic representation of the MANO method."

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
Transfer of miR-223 during neutrophil-epithelial cell interactions

Transfer of miR-223 during neutrophil-epithelial cell interactions
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.

Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.
Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.
Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 2 miRNA181a targets NFAT5 in human CD4+ T cells.

Fig. 2 miRNA181a targets NFAT5 in human CD4+ T cells.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 4. Functional annotation of VUS in EGFR.

Fig. 4. Functional annotation of VUS in EGFR.
Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.
Fig. 6. Pathway analysis of CMLD

Fig. 6. Pathway analysis of CMLD
Fig. 3. BET inhibition reduces homologous recombination.

Fig. 3. BET inhibition reduces homologous recombination.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Similar presentations

Ads by Google